Free Trial
NYSE:CNMD

CONMED (CNMD) Stock Price, News & Analysis

CONMED logo
$60.99 -0.32 (-0.52%)
Closing price 02/21/2025 03:59 PM Eastern
Extended Trading
$61.22 +0.23 (+0.38%)
As of 02/21/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CONMED Stock (NYSE:CNMD)

Key Stats

Today's Range
$59.50
$61.53
50-Day Range
$60.99
$74.35
52-Week Range
$59.50
$86.96
Volume
575,985 shs
Average Volume
508,957 shs
Market Capitalization
$1.89 billion
P/E Ratio
14.38
Dividend Yield
1.31%
Price Target
$77.20
Consensus Rating
Moderate Buy

Company Overview

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

CONMED Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

CNMD MarketRank™: 

CONMED scored higher than 96% of companies evaluated by MarketBeat, and ranked 45th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CONMED has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CONMED has only been the subject of 4 research reports in the past 90 days.

  • Read more about CONMED's stock forecast and price target.
  • Earnings Growth

    Earnings for CONMED are expected to grow by 16.55% in the coming year, from $4.35 to $5.07 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CONMED is 14.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.53.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CONMED is 14.38, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.38.

  • Price to Earnings Growth Ratio

    CONMED has a PEG Ratio of 1.83. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    CONMED has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about CONMED's valuation and earnings.
  • Percentage of Shares Shorted

    8.25% of the outstanding shares of CONMED have been sold short.
  • Short Interest Ratio / Days to Cover

    CONMED has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in CONMED has recently increased by 9.44%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CONMED pays a meaningful dividend of 1.30%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    CONMED does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of CONMED is 18.87%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, CONMED will have a dividend payout ratio of 15.78% next year. This indicates that CONMED will be able to sustain or increase its dividend.

  • Read more about CONMED's dividend.
  • Percentage of Shares Shorted

    8.25% of the outstanding shares of CONMED have been sold short.
  • Short Interest Ratio / Days to Cover

    CONMED has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in CONMED has recently increased by 9.44%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    CONMED has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for CONMED this week, compared to 4 articles on an average week.
  • Search Interest

    1 people have searched for CNMD on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added CONMED to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CONMED insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,795.00 in company stock.

  • Percentage Held by Insiders

    Only 6.80% of the stock of CONMED is held by insiders.

  • Read more about CONMED's insider trading history.
Receive CNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CONMED and its competitors with MarketBeat's FREE daily newsletter.

CNMD Stock News Headlines

Elon’s “New Gold”
MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.
Conmed downgraded to Neutral from Overweight at JPMorgan
JP Morgan Downgrades CONMED (CNMD)
See More Headlines

CNMD Stock Analysis - Frequently Asked Questions

CONMED's stock was trading at $68.44 at the start of the year. Since then, CNMD shares have decreased by 10.9% and is now trading at $60.99.
View the best growth stocks for 2025 here
.

CONMED Co. (NYSE:CNMD) released its earnings results on Wednesday, February, 5th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.14. CONMED had a trailing twelve-month return on equity of 14.31% and a net margin of 10.13%.

Top institutional shareholders of CONMED include Vanguard Group Inc. (11.57%), Earnest Partners LLC (9.10%), Capital Research Global Investors (5.11%) and Champlain Investment Partners LLC (4.21%). Insiders that own company stock include Daniel S Jonas, Pat Beyer, Brian Concannon, Curt R Hartman, Peter K Shagory, Barbara J Schwarzentraub, Johonna Marie Pelletier, John D Ferrell, Stanley W Peters III, Richard Glaze and Todd W Garner.
View institutional ownership trends
.

Shares of CNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CONMED investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Ex-Dividend for 1/3 Dividend
12/20/2024
Dividend Payable
1/03/2025
Last Earnings
2/05/2025
Today
2/22/2025
Next Earnings (Estimated)
4/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
Medical Equipment
Employees
4,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$77.20
High Stock Price Target
$91.00
Low Stock Price Target
$70.00
Potential Upside/Downside
+26.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$132.42 million
Pretax Margin
12.47%

Debt

Sales & Book Value

Annual Sales
$1.31 billion
Cash Flow
$6.50 per share
Book Value
$31.15 per share

Miscellaneous

Free Float
28,790,000
Market Cap
$1.89 billion
Optionable
Optionable
Beta
1.46
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NYSE:CNMD) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners